Metastatic Oral Cavity Squamous Cell Carcinoma

8 clinical trials · Condition

Record	Firm	Date
Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (NCT05172258)	National Cancer Institute (NCI)	2022-07-26
Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (NCT04862650)	Marcelo Bonomi	2021-11-30

Every clearance here is in the API, with alerts when new ones post.